Table 1.

CYP2C19 Phenotype-Determined Exposure Ratios and Selective Serotonin Reuptake Inhibitor Dose Equivalents

Medication	CYP2C19 phenotype	Exposure ratio	Calculated dose equivalent (mg/day)	Formulated (available) dose equivalent (mg/day)
Escitaloprama	Poor metabolizer	1.94	10	10
	Intermediate metabolizer	1.25	15	15
	Normal metabolizer	1	20	20
	Rapid metabolizer	0.86	23.3	20
	Ultrarapid metabolizer	0.64	31.3	30
Sertralineb	Poor metabolizer	2.89	51.94	50
	Intermediate metabolizer	1.38	122.62	125
	Normal metabolizer	1	150	150
	Rapid metabolizer	0.79	189.00	175
	Ultrarapid metabolizer	0.63	238.02	225

Reference doses of 20 and 150 mg/day were used for escitalopram and sertraline, respectively, as these represent the maximum doses in the registration study of escitalopram in adolescent MDD and the approximate average dose in POTS and the Child/Adolescent Anxiety Multimodal Study (CAMS).

^aAdapted from Chang et al. 2014.

^bAdapted from Wang et al. 2001.

MDD, major depressive disorder.